The DayOne Digital Health Accelerator Program
DayOne focus on healthcare innovation driven by digital health solutions. Together with … Continue reading “The DayOne Digital Health Accelerator Program”
DayOne focus on healthcare innovation driven by digital health solutions. Together with … Continue reading “The DayOne Digital Health Accelerator Program”
London, UK – 21 October 2021 – Leucid Bio (“Leucid” or the “Company”), … Continue reading “Leucid Bio Raises £11.5M in Series A Financing to Develop Next Generation of Innovative Chimeric Antigen Receptor T cell (CAR-T) Therapies”
Industry veteran in oncology antibody discovery & development Dr Haijun Sun appointed … Continue reading “ONA Therapeutics Strengthens Scientific Leadership Team”
Funds will be used to support the development of pioneering mammary biotechnology … Continue reading “Novo Holdings Leads US$21M Series A Financing in BI-OMILQ”
October 18, 2021 Early data from Phase 1/2 clinical trial in pediatric … Continue reading “LogicBio Therapeutics Announces Early Clinical Trial Results Demonstrating First-Ever In Vivo Genome Editing in Children”
CAMBRIDGE, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) — Pyxis Oncology, Inc. (Nasdaq: PYXS), a preclinical oncology … Continue reading “Pyxis Announces Pricing of Upsized Initial Public Offering”
LONDON, 18 October 2021: Arix Bioscience plc (“Arix” or the “Company”) (LSE: … Continue reading “Arix Bioscience plc Business Update and Cancellation of Share Buyback”
Major US hospital-based clinical trial highlights benefit of nasal decolonization to reduce … Continue reading “Destiny Pharma: Major US hospital-based clinical trial highlights benefit of nasal decolonization to reduce ICU infections caused by Staphylococcus aureus”
ALAMEDA, Calif. & CAMBRIDGE, UK – October 14, 2021 – Exelixis, Inc. (Nasdaq: … Continue reading “Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes”
Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative … Continue reading “Futura Medical plc Board Appointment”
– Completed enrolment of 150 pregnant women in a Phase 2 study … Continue reading “MinervaX provides clinical and leadership update”
Mårten Steen Promoted to Co-Managing Partner Expanded team with the appointment of … Continue reading “HEALTHCAP STRENGTHENS SENIOR TEAM”
LONDON, 6 October 2021: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), … Continue reading “Arix today announces the following updates to its Board and Executive team”
Industry veteran with decades of experience in company formation, scientific research, and … Continue reading “Centessa Pharmaceuticals Appoints David Grainger, PhD, a Leading Biotech Entrepreneur, as Chief Innovation Officer”
The Hague, Netherlands, 5 October 2021: Amber Implants, an innovative medical technology company … Continue reading “Amber Implants VCFix® spinal system receives US FDA Breakthrough Designation”
DelSiTech Awarded UnitaidExplore Funding for Innovations in Paediatric Healthcare For development of … Continue reading “DelSiTech Awarded UnitaidExplore Funding for Innovations in Paediatric Healthcare”
Torsten Mummenbrauer, Chief Executive Officer of ExeVir will be speaking on a … Continue reading “ExeVir Bio BV announces its participation in the 8th Annual Healthtech Investment Forum organized by SACHS Associates taking place virtually 5th-6th October 2021.”
Isabel Ferreira speaking on the “Platform Technologies and Novel Therapeutics” Panel Versameb … Continue reading “Versameb at Sachs 21st Annual Biotech in Europe Forum”
OGA inhibitors offer multimodal mechanism of action with potential for multiple approaches … Continue reading “Asceneuron to Provide Update on O-GlcNAcase Pipeline at Upcoming Conferences”
For more information about Optimum Strategic Communications, please get in touch
We'd love to hear from you...
GET IN TOUCH
© Copyright 2021 Optimum Strategic Communications All rights reserved.
The Spice Building
8 Devonshire Square
London
EC2M 4PL
Tel: +44 (0)203 950 9144
Email: contact@optimumcomms.com
